In premature infants, oxygen toxicity and antioxidant deficiencies contribute to the development of bronchopulmonary dysplasia (BPD). Dr. Trent Tipple, principal investigator in the Center for Perinatal Research, and his lab recently demonstrated that pharmacologic thioredoxin reductase (TrxR) inhibition enhances antioxidant responses and improves survival in adult oxidant lung injury models. Ongoing preclinical studies will determine the safety and efficacy of TrxR inhibition as a novel approach to attenuate oxygen-mediated neonatal lung injury. Their findings will establish the rationale for future investigations of TrxR inhibitors to prevent BPD, a significant and costly cause of morbidity in preterm infants.
Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arnér ES, Tipple TE. Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: implications for oxidant-induced lung injury. Antioxid Redox Signal. 2012 Nov 15;17(10):1407-16. doi: 10.1089/ars.2011.4377. Epub 2012 Jun 25.
Contact: Trent Tipple